Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Chin J Integr Med. 2017 Dec;23(12):937-942. doi: 10.1007/s11655-017-2279-1. Epub 2017 May 27.
To observe the clinical effects of Babaodan Capsule (, BBD) combined with Qingyi Huaji Formula (, QYHJ) in treating patients with advanced pancreatic cancer.
Eighty-one patients with advanced pancreatic cancer (from January 1, 2013 to December 31, 2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group (40 cases) and QYHJ only group (41 cases), and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment.
The cancer-related symptoms of patients such as ascites, jaundice, pain, abdominal distension, anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group (P<0.01). In addition, the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group (65% vs. 33%, respectively, P=0.0023).
BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However, it deserves to be further investigated in randomized clinical trials.
观察八丹丹胶囊联合清胰化瘀方治疗晚期胰腺癌的临床疗效。
纳入 2013 年 1 月 1 日至 2014 年 12 月 31 日期间 81 例晚期胰腺癌患者，采用随机数字表法分为两组，每组 40 例，两组均采用 QYHJ 治疗，QYHJ 加 BBD 组加用八丹丹胶囊，比较两组患者的生存状况及治疗 2 个周期后肿瘤相关症状的变化。
与 QYHJ 组相比，QYHJ 加 BBD 组患者腹水、黄疸、疼痛、腹胀、纳差及 Karnofsky 行为状态评分均明显改善（P<0.01）。此外，QYHJ 加 BBD 组患者 1 年生存率高于 QYHJ 组（65%比 33%，P=0.0023）。
BBD 联合 QYHJ 治疗晚期胰腺癌可延长患者的生存时间，值得进一步开展随机对照临床试验研究。
